SCHEMBL6169045

SCHEMBL6169045

Fc1cc(F)cc(C2(c3ccc(N4CCCCC4)cc3)C=Cc3c(cc(N4CCOCC4)c4ccccc34)O2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
NPSR1 Q6W5P4 3/20 0.38
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 4/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
BLM P54132 1/20 0.35
BACE1 P56817 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6761051 1.00 ALDH1A1 (0.38) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL21338487 0.93 ALDH1A1 (0.37) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL12205327 0.93 ALDH1A1 (0.37) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL12206758 0.93 ALDH1A1 (0.37) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL8506443 0.92 NPSR1 (0.40) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL2412684 0.91 ALDH1A1 (0.41) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL29501170 0.91 ALDH1A1 (0.41) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL2599669 0.90 KDM4E (0.39) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL14092910 0.89 SMN1; SMN2 (0.33) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA
SCHEMBL675528 0.89 MAPT (0.36) ALDH1A1NPSR1KDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559713-A1 Chromene compound Tokuyama Corporation (JP) 2005-08-03 EP disclosed
EP-1122251-B1 CHROMENE COMPOUNDS TOKUYAMA CORP (JP) 2005-07-20 EP disclosed
US-6525194-B1 Naphtho-2,1-b-pyran derivative that develops yellow to red color TOKUYAMA CORPORATION (JP) 2003-02-25 US disclosed
US-20030028019-A1 Chromene compound MOMODA JUNJI (JP) 2003-02-06 US disclosed
EP-1122251-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030028019-A1 Chromene compound MITF, TYR, CDYL ALDH1A1 4063/4885NPSR1 4153/4885KDM4E 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.